Vanta Bioscience P/E Ratio
Current P/E Ratio
130.93
High Valuation
Very High - High growth expectations or significantly overvalued
Vanta Bioscience (VANTABIO) P/E ratio is 130.93 (High), EPS (TTM) ₹0.15, current price ₹ on None — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see VANTABIO share price screener.
Current Valuation Metrics
P/E Ratio
130.93
Current Price
₹
EPS (TTM)
₹0.15
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
54.06
Sector Median
30.97
Sector Rank
#11 of 198
Sector Percentile
5.6%
Earnings Breakdown (TTM)
TTM EPS
₹-3.95
Mar 2022
₹0.11
Dec 2022
₹-4.06
VANTABIO P/E Ratio — Valuation Signal & Historical Context
Vanta Bioscience P/E 130.93 — signal: Overvalued. Compare with VANTABIO fair price to assess whether the stock is under or overvalued.
- Stock appears overvalued with PE of 130.93, suggesting caution for new investments
- Trading at premium to sector average PE of 54.06
VANTABIO vs Healthcare Peers — P/E Ratio Comparison
Vanta Bioscience P/E 130.93 vs Healthcare average 54.06, median 30.97 — range 2.86–700.0.
Sector Average
54.06
Sector Median
30.97
Lowest P/E
2.86
Highest P/E
700.0
Companies
198
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 2.98 | ₹52 | Low |
| Colinz Laboratories | COLINZ | 3.34 | ₹10 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,329 | Low |
| Sunrest Lifescience | SUNREST | 4.19 | ₹67 | Low |
| GKB Ophthalmics | GKB | 5.81 | ₹32 | Low |
| JFL Life Sciences | JFLLIFE | 5.83 | ₹78 | Low |
| Dipna Pharmachem | DPL | 5.9 | ₹14 | Low |
| Shelter Pharma | SHELTER | 6.3 | ₹57 | Low |
| Royal Sense | ROYAL | 6.73 | ₹48 | Low |